EE175 Cost-Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.444
https://www.valueinhealthjournal.com/article/S1098-3015(23)03574-X/fulltext
Title :
EE175 Cost-Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03574-X&doi=10.1016/j.jval.2023.09.444
First page :
Section Title :
Open access? :
No
Section Order :
12468